Abstract
Introduction: COVID-19 has affected many people worldwide. Effective treatments have been reported using medicinal plants which their multi functionality may beneficial. Considering the importance of innate immune response and pathologic effect of cytokine storm in COVID-19 patients, this study examined the effect of Redcurrant (Ribes rubrum) fruit powder capsules on inflammatory cytokines of IL-6 and TNFα as primary objectives. Moreover, its effect on the COVID-19 patients' recovery symptoms was evaluated. Methods: We analyzed the clinical effect on recovery symptoms, hematological parameters, and the serum levels of interlucin-6 and TNFα in the placebo-controlled and treated patients with Redcurrant fruit powder. Results: Redcurrant fruit powder capsules significantly decreased pro-inflammatory cytokines of IL-6 and TNF-α, and reduced the clinical recovery time of COVID-19 and fatigue (from 7.3 ± 2.09 to 2.9 ± 1.28 days) as well as cough (from 5.67 ± 2.4 to 2.4 ± 1.7) days compared to the control group. Conclusion: Redcurrant fruit powder might be a promising herbal treatment of COVID-19, and since no considerable side effect is observed in short-term usage, it might be beneficial to start treatment as early as possible in suspected cases of COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
IRCT20101201005287N3
Funding Statement
This study was funded by the Tabriz university of medical sciences (grant number 66644)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of Tabriz University of medical sciences approved the study (IR.TBZMED.REC.1400.918), and the project was registered as a clinical trial in Iranian Registry of Clinical Trials (IRCT20101201005287N3)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
